Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Baqsimi ® (glukagon näspulver)
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
After administration of 3 mg NG in adult patients with type 1 diabetes, glucose levels began to rise as early as 5 minutes. By 10 minutes, the median glucose level was above 3.9 mmol/L (70 mg/dL). The mean maximum glucose increase was 7.8 mmol/L (140 mg/dL).1
Glucose Raising Effect in Study 1
Both NG and IM glucagon elicited a similar BG-raising effect (Figure 1).2
Figure 1. Mean Blood Glucose Concentrations After Administration of NG and IM Glucagon2
Abbreviations: IM = intramuscular; IMG = intramuscular glucagon; NG = nasal glucagon (glucagon nasal powder).
Other Parameters
Gender and body weight had no clinically meaningful effect on the pharmacodynamics of NG.1
Common cold with nasal congestion with or without concomitant use of a decongestant did not impact pharmacodynamics of NG.1
1. Baqsimi [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
2. Suico J, Hovelmann U, Zhang S, et al. Nasal glucagon: a viable alternative to treat insulin-induced hypoglycemia in adults with type 1 diabetes. Talk presented at: Proceedings from the European Association for the Study of Diabetes; October 1-5, 2018; Berlin.
Glossary
BG = blood glucose
NG = nasal glucagon (glucagon nasal powder)
PD = pharmacodynamic
Datum fӧr senaste ӧversyn 2019 M07 24